Paragon Bioservices has been awarded a JVAP-CBMS contract from the Department of Defense (DoD) for the vaccine development and subsequent GMP manufacturing of the VEE Replicon Particle Trivalent Filovirus Vaccine. The initial phase of the contract is valued at $15 million, with future optional CLINs that, if exercised, would more than double that amount. Marco Chacon, Ph.D., Paragon’s chief executive officer, commented, “My colleagues and I are honored to be selected for this contra...